Last reviewed · How we verify
TL-118
At a glance
| Generic name | TL-118 |
|---|---|
| Sponsor | Tiltan Pharma Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (PHASE2)
- A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment (PHASE2)
- Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) (PHASE2)
- Investigator's Initiated Phase II Study for Pancreatic Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TL-118 CI brief — competitive landscape report
- TL-118 updates RSS · CI watch RSS
- Tiltan Pharma Ltd. portfolio CI